Skip to main content

Acute Pancreatitis

Gastroenterology
8
Pipeline Programs
11
Companies
13
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
5
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 12 programs with unclassified modality

Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.

$7.3B marketMature→ Stable30 products15 companies

Key Trends

  • AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
  • Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
  • Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds

Career Verdict

Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1LINZESSStable
$1.8B
AbbVie·Peak7.7yr
#2CREONDeclining
$1.5B
AbbVie·LOE Approaching
#3XIFAXANDeclining
$1.1B
Bausch Health·LOE Approaching
#4RINVOQGrowing
$976M
AbbVie·Peak11.8yr
#5XELJANZ XRStable
$586M
Pfizer·Peak8.3yr

Drug Class Breakdown

Unknown Mechanism
$2.5B(34%)

mature portfolio anchor

Guanylate Cyclase Activators
$1.9B(27%)

well-established class

Pancreatic Enzymes
$1.5B(20%)

facing biosimilar competition

Janus Kinase Inhibitors
$976M(13%)

growing IBD adoption

Proton Pump Inhibitors
$107M(1%)

commoditized

Career Outlook

Stable

Gastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.

Breaking In

Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.

For Experienced Professionals

Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.

In-Demand Skills

IBD and IBS indication expertiseJAK inhibitor pharmacologyMedical device integration (diagnostics, endoscopy)Generic/biosimilar launch readinessReal-world evidence generation

Best For

Medical Science Liaison (IBD/IBS focus)Commercial Manager (Generic Launch)Clinical Operations SpecialistMarket Access/Reimbursement StrategistRegulatory Affairs (small molecule focus)

Hiring Landscape

$70K-$213K

Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.

1,818
Open Roles
4
Companies Hiring
3
Departments

Top Hiring Companies

377Growing
293Stable
78Stable

By Department

Engineering(24%)
$169K
Commercial(15%)
$176K
Manufacturing(10%)
$213K

Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.

Competitive Landscape

10 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
3 programs
1
Indomethacin SRPhase 41 trial
Identification of the Impact of Acute Pancreatitis on Quality of LifeN/A1 trial
Invasive intervention for acute pancreatitisN/A1 trial
Active Trials
NCT04222075Unknown200Est. Sep 2022
NCT06023771Recruiting100Est. Dec 2026
NCT03547232Recruiting1,504Est. Dec 2028
Utah Medical
Utah MedicalIreland - Dublin
1 program
1
Lactated Ringer SolutionPhase 41 trial
Active Trials
NCT05781243Completed792Est. Sep 2024
CalciMedica
CalciMedicaLA JOLLA, CA
4 programs
1
3
CM-4620 Injectable Emulsion or CM-4620-IEPhase 21 trial
CM4620 Injectable EmulsionPhase 21 trial
CM4620-IEPhase 21 trial
CM4620Phase 1/21 trial
Active Trials
NCT04195347Recruiting42Est. Jan 2029
NCT04681066Completed216Est. May 2024
NCT03401190Completed21Est. Apr 2019
+1 more trials
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Infusion of 5 mg/kg InfliximabPhase 2Monoclonal Antibody
MSD
MSDIreland - Ballydine
1 program
1
Infusion of 5 mg/kg InfliximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03684278Recruiting290Est. Mar 2027
Philips
PhilipsNetherlands - Amsterdam
1 program
Early discharge with remote home monitoring.N/A1 trial
Active Trials
NCT05501314Unknown70Est. Apr 2025
Interscope
InterscopeMA - Northbridge
1 program
EndoRotor® SystemN/A1 trial
Active Trials
NCT04814693Enrolling By Invitation60Est. Feb 2027
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Proton pump inhibitorN/A1 trial
Active Trials
NCT05817721Completed893Est. Mar 2024
Verona Pharma
Verona PharmaUK - London
1 program
postoperative acute pancreatitis evaluationN/A1 trial
Active Trials
NCT04917172Completed65Est. Jun 2021
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Infusion of 5 mg/kg InfliximabPHASE_2Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
UNION therapeuticsIndomethacin SR
Utah MedicalLactated Ringer Solution
CalciMedicaCM-4620 Injectable Emulsion or CM-4620-IE
MSDInfusion of 5 mg/kg Infliximab
CalciMedicaCM4620-IE
CalciMedicaCM4620 Injectable Emulsion
CalciMedicaCM4620
UNION therapeuticsInvasive intervention for acute pancreatitis
Heidelberg PharmaProton pump inhibitor
PhilipsEarly discharge with remote home monitoring.
InterscopeEndoRotor® System
Verona Pharmapostoperative acute pancreatitis evaluation
UNION therapeuticsIdentification of the Impact of Acute Pancreatitis on Quality of Life

Clinical Trials (13)

Total enrollment: 4,260 patients across 13 trials

Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)

Start: Dec 2024Est. completion: Dec 20281,504 patients
Phase 4Recruiting
NCT05781243Utah MedicalLactated Ringer Solution

Normal Saline Versus Lactated Ringer's Solution for Acute Pancreatitis Resuscitation

Start: Jun 2023Est. completion: Sep 2024792 patients
Phase 4Completed
NCT04681066CalciMedicaCM-4620 Injectable Emulsion or CM-4620-IE

A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Start: Mar 2021Est. completion: May 2024216 patients
Phase 2Completed
NCT03684278MSDInfusion of 5 mg/kg Infliximab

Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)

Start: May 2019Est. completion: Mar 2027290 patients
Phase 2Recruiting

A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis

Start: Jan 2019Est. completion: Jun 20197 patients
Phase 2Completed
NCT03401190CalciMedicaCM4620 Injectable Emulsion

CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS

Start: Mar 2018Est. completion: Apr 201921 patients
Phase 2Completed

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

Start: Sep 2020Est. completion: Jan 202942 patients
Phase 1/2Recruiting
NCT06023771UNION therapeuticsInvasive intervention for acute pancreatitis

Invasive Intervention of Local Complications of Acute Pancreatitis

Start: Oct 2023Est. completion: Dec 2026100 patients
N/ARecruiting
NCT05817721Heidelberg PharmaProton pump inhibitor

PROTon Pump Inhibitors and Stent OCclusion Rate Of Lumen Apposing Metal Stents

Start: May 2023Est. completion: Mar 2024893 patients
N/ACompleted
NCT05501314PhilipsEarly discharge with remote home monitoring.

Remote Home Monitoring Acute Pancreatitis

Start: Oct 2022Est. completion: Apr 202570 patients
N/AUnknown
NCT04814693InterscopeEndoRotor® System

Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis

Start: Sep 2022Est. completion: Feb 202760 patients
N/AEnrolling By Invitation
NCT04917172Verona Pharmapostoperative acute pancreatitis evaluation

Post-Operative Acute Pancreatitis After Pancreaticoduodenectomy

Start: Apr 2019Est. completion: Jun 202165 patients
N/ACompleted
NCT04222075UNION therapeuticsIdentification of the Impact of Acute Pancreatitis on Quality of Life

Identification of the Impact of Acute Pancreatitis on Quality of Life

Start: Aug 2018Est. completion: Sep 2022200 patients
N/AUnknown

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 actively recruiting trials targeting 4,260 patients
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.